Almost every medical assistance provider will tell you they have doctors and nurses in-house. It has become table stakes, and as a differentiator it has stopped meaning very much. The question worth asking a prospective partner is sharper: on a live case, who actually makes the decision?
There is a real difference between clinicians being available and clinicians being in charge.
Available versus accountable
In a clinically-staffed model, coordinators run the case and escalate to a clinician when something looks difficult. The clinical input is real but intermittent, and accountability is diffuse. In a clinically-led model, a named clinical lead owns the case. The clinical judgement sits at the centre of every material decision, from triage to treatment pathway to the mode and timing of repatriation, and one person is accountable for it.
For an insurer, that changes what you can rely on. You are not hoping the right question got escalated. The clinical view is the default, not the exception.
The difference shows up most clearly in what does not get escalated. A coordinator escalates what looks difficult, and looking difficult is not the same as being difficult. A patient who is comfortable, stable and improving does not look like a problem. If they have been in a private bed for nine days with no documented plan for discharge, they are one, and the person best placed to notice is a clinician reading the notes rather than a coordinator reading a status field.
What it looks like on a real case
Take an ordinary one. A member is admitted overseas after a fall. Imaging shows a fracture that will need fixing. The treating team proposes surgery in three days, when their preferred surgeon is next on the list, and meanwhile keeps the patient in.
In a clinically-staffed model, that is a routine authorisation. There is nothing to escalate. The treatment is indicated, the cost is within tolerance, and the coordinator’s job is to confirm cover and move on. Three days of inpatient bed pass unremarked, and if the surgeon’s list slips, so do they.
In a clinically-led model, a clinician reads the same information and asks a different set of questions. Does this fracture need fixing in three days or in ten? Is the patient safe to be discharged and readmitted, or is the bed doing something? Is there another surgeon on the list tomorrow? Could this be fixed at home, by a UK team who will also do the follow-up and the rehabilitation?
None of those questions is about refusing care. Every one of them is about the pathway. And each has a materially different answer depending on the clinical picture, which is precisely why a fee schedule cannot answer them.
Why it matters more now
The market is shifting from reactive claims handling towards proactive, pre-claim clinical intelligence: engaging before the treatment, not after the bill. That shift only works if clinicians are driving the case in real time. You cannot influence a treatment pathway you are only reviewing retrospectively.
The objection worth taking seriously
There is a reasonable counter-argument, and it deserves a straight answer: clinicians are expensive, slower than a process, and inconsistent with each other. Three consultants will give you three opinions on a marginal case. A coordinator following a protocol is cheaper, faster and reproducible.
That is true, and it is why clinical leadership needs structure rather than just seniority. A named clinical lead with sole accountability removes the committee problem. A defined escalation ladder with stated times removes the availability problem. Documenting the rationale at the point of decision removes the inconsistency problem, because a reasoning that has to be written down is a reasoning that has to hold together.
What structure cannot do is substitute for the judgement itself. A protocol encodes the decisions somebody has already anticipated. The cases that cost the most, clinically and financially, are the ones nobody anticipated.
Defensibility follows from it
When decisions are clinically led and recorded as they are made, defensibility comes for free. Ask why a patient was moved when they were, or why a particular pathway was chosen, and there is a clinician’s reasoning on the record, not an after-the-fact rationalisation. For high-acuity and high-value cases, that is exactly the assurance insurers and their regulators are looking for.
The question to actually ask
If you are assessing a provider, “do you have clinicians in-house” will get you a yes from everyone. These get you further:
- Who owns a case, by name, and for how long? If the answer describes a rota rather than a person, the case is being handed round.
- What can a clinician overrule? If they can advise but not decide, they are not leading.
- What are your escalation times, and are they commitments or aspirations? Ours are fifteen minutes for clinical escalation and thirty for operational, because a number nobody is held to is not a service level.
- Show me the record of a decision. Not a template. A real case, redacted. Either the reasoning is there in sequence, or it was reconstructed afterwards, and you can tell within about ten seconds which one you are looking at.
Employing clinicians is necessary. Letting them lead is what actually changes the outcome, and the cost. If you want the fuller picture of how that works across a caseload rather than a case, see complex case management.
